SB-431542

SB-431542

Identifiers
ChEBI	CHEBI:91108
ChEMBL	ChEMBL440084
ChemSpider	3716512
IUPHAR/BPS	8216
Jmol interactive 3D	Image
PubChem	4521392
InChI InChI=1S/C22H16N4O3/c23-21(27)13-4-6-14(7-5-13)22-25-19(20(26-22)16-3-1-2-10-24-16)15-8-9-17-18(11-15)29-12-28-17/h1-11H,12H2,(H2,23,27)(H,25,26) Key: FHYUGAJXYORMHI-UHFFFAOYSA-N InChI=1/C22H16N4O3/c23-21(27)13-4-6-14(7-5-13)22-25-19(20(26-22)16-3-1-2-10-24-16)15-8-9-17-18(11-15)29-12-28-17/h1-11H,12H2,(H2,23,27)(H,25,26) Key: FHYUGAJXYORMHI-UHFFFAOYAN
SMILES NC(=O)c1ccc(cc1)c2nc(c3ccc4OCOc4c3)c([nH]2)c5ccccn5
Properties
Chemical formula	C22H16N4O3
Molar mass	384.4
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references

SB-431542 is a drug candidate developed by GlaxoSmithKline (GSK) as an inhibitor of the activin receptor-like kinase (ALK) receptors, ALK5, ALK4 and ALK7.^[1] (It is NOT an ALK inhibitor).

In-vitro studies

It also suppressed the TGF-beta-induced proliferation of osteosarcoma cells in humans.^[1]

As of January 2016 There are no clinical trials registered for SB-431542 for cancer or any other indication.^[2]

In vitro use

The treatment with SB431542 is a robust, clinically applicable, and efficient system for generating mesenchymal stem/stromal cells (MSCs) from human iPSCs.^[3]

References

1. Laping, NJ; Grygielko E; Mathur A; Butter S; Bomberger J; Tweed C; Martin W; Fornwald J; Lehr R; Harling J; Gaster L; Callahan JF; Olson BA (2002). "Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542". Molecular Pharmacology 62 (1): 58–64. doi:10.1124/mol.62.1.58. PMID 12065755.
2. Search results for SB-431542
3. Chen Y S, Pelekanos R A., Ellis R L., et al and Nicholas M. Fisk (2012). Small Molecule Mesengenic Induction of Human Induced Pluripotent Stem Cells to Generate Mesenchymal Stem/Stromal Cells Stem Cells Trans Med., 1(2), 83-95 doi:10.5966/sctm.2011-0022